Literature DB >> 26294351

Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance.

M C Amato1, R Vesco1, E Vigneri1, A Ciresi1, C Giordano2.   

Abstract

PURPOSE: Insulin resistance and compensatory hyperinsulinism are the predominant metabolic defects in polycystic ovary syndrome (PCOS). However, hyperinsulinism, as well as being compensatory, can also express a condition of reduced insulin clearance. Our aim was to evaluate the differences in insulin action and metabolism between women with PCOS (with normal glucose tolerance) and age- and BMI-matched women with prediabetes (without hyperandrogenism and ovulatory disorders).
METHODS: 22 women with PCOS and 21 age/BMI-matched women with prediabetes were subjected to a Hyperinsulinemic-euglycemic clamp and an Oral Glucose tolerance Test (OGTT). Insulin sensitivity was assessed by the glucose infusion rate during clamp (M value); insulin secretion by Insulinogenic index, Oral Disposition Index (DIo) and AUC(2h-insulin) during OGTT; and insulin clearance by the metabolic clearance rate of insulin (MCRI) during clamp.
RESULTS: Women with PCOS showed significantly higher levels of AUC(2h-insulin) (p < 0.011), Insulinogenic Index (p < 0.001), DIo (p = 0.002) and significantly lower levels of AUC(2h-glucos)e (p = 0.001). No difference was found between the two groups regarding insulin sensitivity (M value). Lower levels of MCRI were found in women with PCOS [420 (IQR 227-588) vs. 743 (IQR 597-888) ml m(-2) min(-1): p < 0.001]. Furthermore, in the PCOS group, a strong independent inverse correlation was only observed between MCRI and AUC(2h-insulin) (PCOS: β:-0.878; p < 0.001; Prediabetes: β:-0.501; p = 0.019).
CONCLUSIONS: Our study suggests that in normoglycemic women with PCOS there is peripheral insulin sensitivity similar to that of women with prediabetes. What sets PCOS apart is the hyperinsulinism, today still simplistically defined "compensatory"; actually this is mainly related to decreased insulin clearance whose specific causes and dynamics have yet to be clarified.

Entities:  

Keywords:  Clamp; Hyperinsulinism; Insulin clearance; Insulin resistance; PCOS

Mesh:

Substances:

Year:  2015        PMID: 26294351     DOI: 10.1007/s40618-015-0372-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  45 in total

1.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

Review 2.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

3.  Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.

Authors:  Nigel K Stepto; Samantha Cassar; Anju E Joham; Samantha K Hutchison; Cheryce L Harrison; Rebecca F Goldstein; Helena J Teede
Journal:  Hum Reprod       Date:  2013-01-12       Impact factor: 6.918

4.  Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome.

Authors:  M Ciampelli; A M Fulghesu; F Cucinelli; V Pavone; A Caruso; S Mancuso; A Lanzone
Journal:  Hum Reprod       Date:  1997-09       Impact factor: 6.918

5.  Insulin and C-peptide levels in obese patients with polycystic ovaries.

Authors:  R Pasquali; S Venturoli; R Paradisi; M Capelli; M Parenti; N Melchionda
Journal:  Horm Metab Res       Date:  1982-06       Impact factor: 2.936

6.  Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women.

Authors:  A Dunaif; L Sorbara; R Delson; G Green
Journal:  Diabetes       Date:  1993-10       Impact factor: 9.461

7.  Kinetics of insulin receptor internalization and recycling in adipocytes. Shunting of receptors to a degradative pathway by inhibitors of recycling.

Authors:  S Marshall
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

8.  Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  Carlos Lorenzo; Lynne E Wagenknecht; Marian J Rewers; Andrew J Karter; Richard N Bergman; Anthony J G Hanley; Steven M Haffner
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

9.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

Review 10.  Visceral adiposity index: an indicator of adipose tissue dysfunction.

Authors:  Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2014-04-14       Impact factor: 3.257

View more
  24 in total

1.  Morning blood pressure surge and its relation to insulin resistance in patients of reproductive age with polycystic ovary syndrome.

Authors:  Hasan Kadi; Eyup Avci; Akin Usta; Abdullah Orhan Demirtaş
Journal:  Reprod Biol Endocrinol       Date:  2018-08-09       Impact factor: 5.211

2.  Plasma total oxidant and antioxidant status after oral glucose tolerance and mixed meal tests in patients with polycystic ovary syndrome.

Authors:  Zehra Kucukaydın; Cevdet Duran; Mustafa Basaran; Fatos Camlica; Sami Said Erdem; Ahmet Basaran; Orkide Kutlu; Ferda Sevimli Burnik; Halis Elmas; Mustafa Sait Gonen
Journal:  J Endocrinol Invest       Date:  2016-06-14       Impact factor: 4.256

3.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

4.  The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes.

Authors:  Y Çakıroğlu; F Vural; B Vural
Journal:  J Endocrinol Invest       Date:  2016-03-15       Impact factor: 4.256

5.  Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.

Authors:  M N Kalem; Z Kalem; T Gurgan
Journal:  J Endocrinol Invest       Date:  2017-02-27       Impact factor: 4.256

6.  Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.

Authors:  U Durmus; C Duran; S Ecirli
Journal:  J Endocrinol Invest       Date:  2016-11-12       Impact factor: 4.256

7.  Gly972Arg of IRS-1 and Lys121Gln of PC-1 polymorphisms act in opposite way in polycystic ovary syndrome.

Authors:  M A Pappalardo; R Vita; F Di Bari; M Le Donne; F Trimarchi; S Benvenga
Journal:  J Endocrinol Invest       Date:  2016-10-26       Impact factor: 4.256

8.  Clinical significance of ADAMTS1, ADAMTS5, ADAMTS9 aggrecanases and IL-17A, IL-23, IL-33 cytokines in polycystic ovary syndrome.

Authors:  M Karakose; K Demircan; E Tutal; T Demirci; M S Arslan; M Sahin; H T Celik; F Kazanci; J Karakaya; E Cakal; T Delibasi
Journal:  J Endocrinol Invest       Date:  2016-05-04       Impact factor: 4.256

9.  Evidence for decreased expression of APPL1 associated with reduced insulin and adiponectin receptors expression in PCOS patients.

Authors:  R Dehghan; M Saidijam; N Shabab; M Yavangi; T Artimani
Journal:  J Endocrinol Invest       Date:  2016-04-13       Impact factor: 4.256

10.  Metabolomic Profiles of Overweight/Obesity Phenotypes During Adolescence: A Cross-Sectional Study in Project Viva.

Authors:  Wei Perng; Sheryl L Rifas-Shiman; Joanne Sordillo; Marie-France Hivert; Emily Oken
Journal:  Obesity (Silver Spring)       Date:  2019-12-26       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.